Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: VIETNAM - REVIEW
The macroenvironment is positive for Vietnam's pharmaceutical market growth, despite concerns over IPR. Economically, the Economist Intelligence Unit projects Vietnam's GDP to be one of the smallest in the Asia Pacific region by 2016, ranked 15th. Legally, despite Vietnam remaining on the USTR Special 301 Watch List in 2011, the USA is encouraged by the government's attempts to improve IPR protection and its enforcement; particularly of note are recent amendments to the IP Law. Demographically, Vietnam has a large and young population, which will be the eighth largest population in the Asia Pacific region by 2016. The elderly population is rising, albeit slowly, and will remain one of the lowest proportions in the Asia Pacific region.
The Drug Administration of Vietnam (DAV) has warned that drug prices could rise slightly in 2011 due to volatile raw material prices and the VND-US$ exchange rate. The Vietnam Pharmaceutical Companies Association (VNPCA) forecasts higher sales prices for both imported and domestic drugs in 2011, due to higher input costs and rising world prices. To review the local pharmaceutical market and prevent large drug price increases, the DAV has announced several measures. Accordingly, the DAV will step-up the inspection of drug price quotations by pharmaceutical companies through health workgroups and will promptly publish the results. The DAV will also supervise the enforcement of state regulations on drug price management and exercise sanctions on violators.
Rising drug consumption and government investment make Vietnam an attractive pharmaceutical market. Drug consumption in per capita terms is expected to increase by around 70% in 2014. In terms of output, Espicom estimates that pharmaceutical production has increased by a CAGR of over 25% during the period 2005 to 2010. The government has announced that improving the domestic pharmaceutical industry is the health sector's highest priority over the next few years. A plan to develop and restructure Vietnam's pharmaceutical industry is underway, which includes boosting the production of essential drugs in order to cut prices, stabilise the market and reduce the country's dependence on foreign pharmaceutical imports.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
